price

GSI Commerce has a potential upside of 39.1% based on a current price of $22.24 and an average consensus analyst price target of $30.93.

GSI Commerce is currently below its 50-day moving average (MA) of $23.32 and below its 200-day MA of $25.10.

GSI Commerce (NASDAQ:GSIC) reported Q4 EPS of $0.57, topping consensus estimates of $0.51 per share. Revenues for the quarter rose 25% year-over-year to $537.0 million, ahead of consensus estimates of $532.9 million.

The bank sees 2011 EPS of $0.77, down from $0.86 per share, and 2012 EPS of $1.28, up from $1.12 per share.

OpenTable is currently above its 50-day moving average (MA) of $75.14 and above its 200-day of $57.89.

Morgan Stanley adjusted its 2011 and 2012 EPS estimates for OpenTable (NASDAQ:OPEN) and maintained its equal-weight rating.

Morgan Stanley lowered its 2011 and 2012 EPS estimates for DuPont (NYSE:DD) and maintained its equal-weight rating and $56 price target. The bank sees 2011 EPS of $3.65, down from $3.71 per share, and 2012 EPS of $4.03, down from

Morgan Stanley lowered its 2011 and 2012 EPS estimates for Teva Pharmaceutical Industries (NASDAQ:TEVA) and maintained its equal-weight rating. The bank sees 2011 EPS of $5.05, down from $5.29 per share, and 2012 EPS of $5.78, do

Revenue Cycle Manager enables error correction at every stage, unlike legacy applications that resolve errors at the end-stages of the revenue cycle, or point solutions that take limiting approaches at some stages, the company sai

Shares are down 0.36% or $38.47.

Pegasystems (PEGA) today announced the launch of its new Revenue Cycle Manager solution for the health care market, which it says allows health care systems to streamline patient billing, boost cash flow and drive down operational

Morgan Stanley lowered its 2011 and 2012 EPS estimates for Sara Lee (NYSE:SLE) and maintained its equal-weight rating and $14.50 price target. The bank sees 2011 EPS $0.85, down from $0.89 per share, and 2012 EPS of $1.00, down fr

The bank sees 2012 EPS of $1.98, up from $1.97 per share.

Illumina has a potential upside of 5% based on a current price of $70.25 and an average consensus analyst price target of $73.73.

Illumina is currently above its 50-day moving average (MA) of $66.13 and above its 200-day of $51.55.

Morgan Stanley raised its 2012 EPS estimate for Illumina (NASDAQ:ILMN) and maintained its overweight rating and $78 price target.